Abstract
An expansion of CD21low B cells has been described in a variety of diseases associated with persistent immune stimulation as in chronic infection, immunodeficiency, or autoimmunity. Different developmental stages of CD21low B cells have been highlighted in specific diseases; however, a systematic comparison of distribution, phenotype, and signaling capacity of these populations has not yet been performed to delineate the pivotal character of this unusual B cell population. Screening of more than 200 patients with autoimmune disease demonstrated that the prevalence of patients with expanded CD21low B cells varies between diseases. The expansion was frequent in patients with systemic lupus erythematosus, in which it correlated to relative B cell lymphopenia and duration of disease. Different proportions of distinct developmental stages of CD21low B cells co-occur in nearly all patients with autoimmune disease. Although in most patients, naive-like and CD27- switched memory B cells were the most prominent CD21low subpopulations, there was no detectable association of the pattern with the underlying disease. Despite their distinct developmental stage, all CD21low B cells share a common core phenotype including the increased expression of inhibitory receptors, associated with an elevated constitutive phosphorylation of proximal signaling molecules downstream of the BCR but impaired Ca2+ mobilization and NF-κB activation after BCR stimulation. Further, this was accompanied by impaired upregulation of CD69, although CD86 upregulation was preserved. Beyond maturation-associated differences, the common core characteristics of all CD21low B cell populations suggests either a common ancestry or a shared sustained imprint by the environment they originated in.
Highlights
Why The JI? Submit online. Rapid Reviews! 30 days* from submission to initial decision No Triage! Every submission reviewed by practicing scientists Fast Publication! 4 weeks from acceptance to publicatio
In 69 patients (31.7%), we found an increase in the proportion of CD21low B cells of .7.3% of all B cells
An increased proportion of CD21low B cells has been identified in a variety of autoimmune disorders, including connective tissue disease (CTD) like systemic lupus erythematosus (SLE) and primary Sjogren syndrome (pSS), rheumatoid arthritis (RA), and associated vasculitis (AAV) [3,4,5, 24], but data comparing number, phenotype, and function between the different autoimmune disorders are scarce
Summary
The composition of distinct subpopulations within the CD21low population defined by the expression of CD27, IgM, and IgG was determined for 29 autoimmune CD21low patients (15 patients diagnosed with RA, 7 with SLE, 3 with other CTDs, and 4 with AAV) as well as for 24 HD (for gating strategy, see Supplemental Fig. 1 and Materials and Methods). The few CD21low B cells of HD displayed similar phenotypic changes like patient-derived CD21low B cells when compared with the respective CD21pos population (Supplemental Fig. 2A and data not shown).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have